A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.

Yuri Taniguchi Tsuneo Shimokawa Yuichi Takiguchi Toshihiro Misumi Yukiko Nakamura Yosuke Kawashima Naoki Furuya Yoshimasa Shiraishi Toshiyuki Harada Hisashi Tanaka Satoru Miura Ayumi Uchiyama Hideyuki Niwa Takaaki Tokito Katsuhiko Naoki Akihiro Bessho Yasuhiro Goto Masahiro Seike Hiroaki Okamoto

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Despite a slightly elevated toxicity, the addition of docetaxel to nivolumab has significantly prolonged the OS and PFS of patients with previously treated ICI-naïve NSCLC.

Keyphrases

small cell lung cancer
locally advanced
advanced non small cell lung cancer
squamous cell carcinoma
radiation therapy
tyrosine kinase